We are redefining natural product drug discovery through AI-driven bioinformatics. Our proprietary platform integrates multi-omics data with machine learning to predict interactions between natural compounds and biological targets.
Focusing on high unmet medical needs, including rare diseases and cancer, we accelerate the path from discovery to therapeutic development.
Advanced algorithms predict compound-target interactions from complex biological datasets, accelerating drug discovery.
Comprehensive knowledge graphs link genes, metabolites, and pathways to prioritize novel therapeutics.
Identify high-potential natural products prior to laboratory validation, reducing time and cost.
Predict natural products targeting critical cancer pathways.
Discover compounds addressing unmet therapeutic needs in rare and genetic diseases.
Enable predictive identification of novel therapeutics for infections and immune-related diseases.
Visit our LinkedIn page to learn more about Evoquant LLC, connect with our team, and explore our technology.
Visit Our LinkedInPortions of the work conducted at Evoquant are supported by the National Institutes of Health under Award Number 1R43AT013358-01A1. For more information, see NIH RePORTER Project Details .
Disclaimer: The content on this site is solely the responsibility of Evoquant and does not necessarily represent the official views of the National Institutes of Health.